[Question] Sweden — has anyone got a straight answer on denial
Genuinely asking, not being difficult.
Everyone in c/glp1muscle repeats that appeal is important. I believe it, but I have never seen anyone show why, and when I search I get 3 threads of people agreeing with each other.
Is there a paper? Is there a measurement? Or is this one of those things that is true because it has been repeated since 2023?
I am not trying to be the "source?" guy. I would just like a source.
best — the order this archive was captured in
Which plan type? copay is different.
formulary exclusions are negotiable sometimes
Yeah, the denial code matters, it tells you what to fight.
the carve-out clause varies by employer
the carve-out clause varies by employer
Yes, exactly this, and it is the bit that took me 72 weeks to accept.
denial reason codes matter, ask for the actual code
Disagree but this is the good kind of wrong — it is specific enough to be checked.
external review is the appeal after insurance says no
Yeah, the denial code matters, it tells you what to fight.
say which country and which plan type
external review is the appeal after insurance says no
Mechanistically the bit that matters is appeal. It explains most of the early profile and a decent chunk of the outcome.
Mechanistically the bit that matters is appeal.
Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.
external review is the appeal after insurance says no
That is net peptide content, not purity. Different number, different meaning.
Dead space in the needle hub holds a small but non-trivial volume. On low-volume draws that can be several units.
Yeah, the denial code matters, it tells you what to fight.
External review overturned the denial. Took 10 weeks but the process exists.
- 1Which plan type? copay is different.7 comments in this branch · started by u/kian_balogun
- 2Disagree but this is the good kind of wrong — it is specific enough to be…5 comments in this branch · started by u/arne_amankwah